These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 21397718

  • 1. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
    Westdijk J, Brugmans D, Martin J, van't Oever A, Bakker WA, Levels L, Kersten G.
    Vaccine; 2011 Apr 18; 29(18):3390-7. PubMed ID: 21397718
    [Abstract] [Full Text] [Related]

  • 2. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
    Kersten G, Hazendonk T, Beuvery C.
    Vaccine; 1999 Apr 09; 17(15-16):2059-66. PubMed ID: 10217607
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA.
    Vaccine; 2013 Nov 12; 31(47):5531-6. PubMed ID: 24063976
    [Abstract] [Full Text] [Related]

  • 4. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R.
    Vaccine; 2018 Nov 12; 36(46):6979-6987. PubMed ID: 30314910
    [Abstract] [Full Text] [Related]

  • 5. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA, McInnis J, Albrecht P.
    Biologicals; 1993 Jun 12; 21(2):169-77. PubMed ID: 8297601
    [Abstract] [Full Text] [Related]

  • 6. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
    Crawt L, Atkinson E, Tedcastle A, Pegg E, sIPV Study Group, Minor P, Cooper G, Rigsby P, Martin J.
    J Infect Dis; 2020 Feb 03; 221(4):544-552. PubMed ID: 30788503
    [Abstract] [Full Text] [Related]

  • 7. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
    Kouiavskaia D, Puligedda RD, Dessain SK, Chumakov K.
    J Virol Methods; 2020 Feb 03; 276():113785. PubMed ID: 31765719
    [Abstract] [Full Text] [Related]

  • 8. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA.
    Vaccine; 2011 Sep 22; 29(41):7188-96. PubMed ID: 21651934
    [Abstract] [Full Text] [Related]

  • 9. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.
    Eggers M, Terletskaia-Ladwig E, Rabenau HF, Doerr HW, Diedrich S, Enders G, Enders M.
    BMC Infect Dis; 2010 Dec 09; 10():347. PubMed ID: 21143885
    [Abstract] [Full Text] [Related]

  • 10. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
    Sawyer LA, Wood D, Ferguson M, Crainic R, Beuvery EC, McInnis J, Albrecht P.
    Biologicals; 1997 Sep 09; 25(3):299-306. PubMed ID: 9324998
    [Abstract] [Full Text] [Related]

  • 11. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.
    Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G.
    Vaccine; 2013 Feb 18; 31(9):1298-304. PubMed ID: 23313617
    [Abstract] [Full Text] [Related]

  • 12. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
    Murakami K, Fujii Y, Someya Y.
    Vaccine; 2020 Apr 09; 38(17):3295-3299. PubMed ID: 32197923
    [Abstract] [Full Text] [Related]

  • 13. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T.
    Vaccine; 2007 Oct 10; 25(41):7041-6. PubMed ID: 17825459
    [Abstract] [Full Text] [Related]

  • 14. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.
    Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M.
    Vaccine; 2011 Jan 17; 29(4):644-9. PubMed ID: 21134451
    [Abstract] [Full Text] [Related]

  • 15. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
    Shirato H, Someya Y, Ochiai M, Horiuchi Y, Takahashi M, Takeda N, Wakabayashi K, Ouchi Y, Ota Y, Tano Y, Abe S, Yamazaki S, Wakita T, sIPV Evaluation Group of NIID-Virology II.
    Vaccine; 2014 Sep 08; 32(40):5163-9. PubMed ID: 25090648
    [Abstract] [Full Text] [Related]

  • 16. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y, Abe S, Yamamoto H, Horie H, Ohyama H, Satoh K, Tano Y, Ota Y, Miyazawa M, Wakabayashi K, Hashizume S.
    Dev Biol (Basel); 2001 Sep 08; 105():163-9. PubMed ID: 11763324
    [Abstract] [Full Text] [Related]

  • 17. Chitosan as an adjuvant for poliovaccine.
    Ghendon Y, Markushin S, Akopova I, Koptiaeva I, Krivtsov G.
    J Med Virol; 2011 May 08; 83(5):847-52. PubMed ID: 21412793
    [Abstract] [Full Text] [Related]

  • 18. Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.
    Donadei A, Kraan H, Ophorst O, Flynn O, O'Mahony C, Soema PC, Moore AC.
    J Control Release; 2019 Oct 08; 311-312():96-103. PubMed ID: 31484041
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.
    J Infect Dis; 2004 Oct 15; 190(8):1404-12. PubMed ID: 15378432
    [Abstract] [Full Text] [Related]

  • 20. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
    Rezapkin G, Martin J, Chumakov K.
    Biologicals; 2005 Mar 15; 33(1):29-39. PubMed ID: 15713554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.